Biologics

Aesculap Biologics achieved 50 percent enrollment in its ongoing phase 3 clinical trial of Novocart 3D, an autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee.

The global autologous matrix-induced chondrogenesis market is expected to grow at an 8.6 percent compound annual growth rate by 2024, according to a Persistence Market Research report.

Roger Hartl, MD, professor of neurological surgery and director of spine surgery at Weill Cornell Medicine in New York City, as well as director of the Weill Cornell Medicine Center for Comprehensive Spine Care, discusses the key trends in spine…

Medtronic launched Grafton Demineralized Bone Matrix for spine and orthopedic procedures in Japan.

After reporting lingering shoulder pain, St. Louis Cardinals pitcher Carlos Martinez received a platelet-rich plasma injection at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics and Sports Medicine, the St. Louis Post-Dispatch reports.

Daniel Birk, MD, director of the Neurosurgery Spine Center at Stony Brook (N.Y.) Medicine, discusses the biggest challenges and opportunities in spine device development today.

Neurosurgeons Mario Cahueque, MD, and Enrique Azmitia, MD, performed SpineFrontier's first SacroFuse and NanoFUSE case in Latin America.

Here are the top manufacturers in the orthopedic biomaterials market, according to a Market Expertz report.

Andrew Cordover, MD, a spine surgeon with Andrews Sports Medicine & Orthopaedic Center in Birmingham, Ala., discusses the key technology trends for 2019.

Andrew Hecht, MD, chief of spine surgery at The Mount Sinai Health System in New York City, outlines the key trends and big opportunities in the spine device space moving forward.